文献速递物质与行为成瘾儿童青少年精神

美国青少年与青年医疗补助参保者中兴奋剂使用障碍诊断趋势

Stimulant Use Disorder Diagnoses in Adolescent and Young Adult Medicaid Enrollees.
PubMed 文献 · JAMA Psychiatry · 2026-01-01

该重复横断面研究利用2001至2020年美国42个州医疗补助理赔数据,分析13至29岁参保者中兴奋剂使用障碍诊断比例的变化。结果显示可卡因类兴奋剂使用障碍诊断在青年中保持稳定、在青少年中下降,而非可卡因类精神兴奋剂使用障碍诊断在18至29岁青年中显著上升。

要点

  • 非可卡因类精神兴奋剂使用障碍诊断在18至24岁和25至29岁青年中均大幅上升。
  • 合并注意缺陷多动障碍诊断或兴奋剂处方的患者中,兴奋剂使用障碍诊断更常见。
  • 2020年确诊兴奋剂使用障碍者多数同时合并其他精神障碍或其他物质使用障碍。

核心结论

  • 2001至2020年,美国青年医疗补助参保者中非可卡因类精神兴奋剂使用障碍诊断比例显著上升,可能与处方及非法兴奋剂使用增加和临床识别提高有关。

主要发现

  • 18至24岁非可卡因类精神兴奋剂使用障碍诊断比例从0.09%升至0.49%(PR 5.47,95%CI 5.20-5.75)。
  • 25至29岁该比例从0.13%升至1.63%(PR 12.55,95%CI 11.83-13.31),18至29岁整体从0.10%升至0.91%。
  • 青少年该比例在0.03%至0.07%之间波动;可卡因使用障碍诊断在青年中稳定、在青少年中从0.04%降至0.01%。
  • 合并ADHD诊断或兴奋剂处方者中,可卡因及非可卡因类精神兴奋剂使用障碍诊断频率为其他人群的2至4倍。
  • 2020年确诊兴奋剂使用障碍者中68%至82%合并精神障碍、72%至78%合并其他物质使用障碍。

临床怎么用

  • 提示临床对青年医疗补助人群,尤其合并ADHD或使用兴奋剂处方者,应关注兴奋剂使用障碍的筛查与评估。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: There has been a national increase in fatal and nonfatal overdoses involving stimulants, and 4.5 million US individuals meet criteria for stimulant use disorder (UD), with the highest prevalence in young adults. However, limited information exists on trends in diagnosed stimulant UD. OBJECTIVE: To estimate trends in the proportion of adolescent and young adult Medicaid enrollees diagnosed with a stimulant UD from 2001 to 2020. DESIGN, SETTING, AND PARTICIPANTS: A repeated cross-sectional study (2001-2020) was conducted using administrative health care claims data from Medicaid (public insurance program in US). Publicly insured adolescents (aged 13-17 years) and young adults (aged 18-24 or 25-29 years) from 42 US states were included. Data were analyzed from January 2025 to July 2025. MAIN OUTCOMES AND MEASURES: Stimulant UD was defined as an inpatient or outpatient International Classification of Diseases diagnosis code in the year, with cocaine UD and noncocaine psychostimulant UD evaluated separately. The annual proportion with stimulant UD diagnoses was stratified by age group, sex, race and ethnicity, and presence of attention-deficit/hyperactivity disorder (ADHD) diagnosis or stimulant prescription in the year. Differences comparing 2001 with 2020 were summarized. Characteristics of those diagnosed with stimulant UD in 2020 were described. RESULTS: The sample included 5.7 million (2001) to 16.1 million Medicaid enrollees (2020) per year; in 2020, 54.2% were female, and 7.1 million were adolescents. From 2001 to 2020, the proportion diagnosed with noncocaine psychostimulant UD increased from 0.09% to 0.49% (prevalence ratio [PR], 5.47 [95% CI, 5.20-5.75]) in those aged 18 to 24 years, from 0.13% to 1.63% (PR, 12.55 [95% CI, 11.83-13.31]) for ages 25 to 29 years, and from 0.10% to 0.91% among young adults aged 18 to 29 years. Among adolescents, the proportion diagnosed with noncocaine psychostimulant UD varied between 0.03% and 0.07%. The proportion diagnosed with cocaine UD was stable in young adults (range, 0.17%-0.34% [18-24 years] and 0.53%-0.79% [25-29 years]) and declined in adolescents (from 0.04% to 0.01%). Cocaine and noncocaine psychostimulant UD diagnoses were 2 to 4 times more common in patients with an ADHD diagnosis or stimulant prescription. Most patients diagnosed with a stimulant UD in 2020 were also diagnosed with a mental health disorder (68%-82%) or other substance UD (72%-78%). CONCLUSIONS AND RELEVANCE: The prevalence of noncocaine psychostimulant UD diagnoses in young adult Medicaid patients increased over the last 2 decades, potentially associated with an increasing use of prescription and illicit stimulants along with increased clinical detection. These trends raise concerns given recent rises in stimulant-involved overdose fatalities and stress the need for evidence-based stimulant UD treatments for young people.

来源:JAMA Psychiatry,查看原文。版权归原作者所有。

引用

  1. Bushnell G, Keyes KM, Zhu Y, et al. Stimulant Use Disorder Diagnoses in Adolescent and Young Adult Medicaid Enrollees. JAMA Psychiatry. 2026. PMID: 41091493. doi:10.1001/jamapsychiatry.2025.2864

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。